These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32812288)

  • 1. The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters.
    Guven DC; Sahin TK; Aksoy S
    Breast J; 2020 Dec; 26(12):2435-2436. PubMed ID: 32812288
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters.
    Guven DC; Sahin TK; Aksoy S
    Breast J; 2021 Jan; 27(1):104. PubMed ID: 33274786
    [No Abstract]   [Full Text] [Related]  

  • 3. Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):185-186. PubMed ID: 29125595
    [No Abstract]   [Full Text] [Related]  

  • 4. Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting.
    Criscitiello C; Viale G; Curigliano G
    Curr Opin Oncol; 2017 Nov; 29(6):428-433. PubMed ID: 28872469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting breast cancer with CDK inhibitors.
    Mayer EL
    Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
    Spring L; Bardia A; Modi S
    Discov Med; 2016 Jan; 21(113):65-74. PubMed ID: 26896604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
    Vidula N; Rugo HS
    Clin Breast Cancer; 2016 Feb; 16(1):8-17. PubMed ID: 26303211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibitors of cyclin-dependent kinases (CDK) - a new group of medicines in therapy of advanced breast cancer].
    Sarosiek T
    Pol Merkur Lekarski; 2018 Jan; 44(259):5-9. PubMed ID: 29374415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
    Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU
    Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK4/6 Inhibitors for Advanced Hormone Receptor-Positive Breast Cancer, 2019 and Beyond.
    Layman RM
    J Natl Compr Canc Netw; 2019 Feb; 17(2):190-192. PubMed ID: 30787131
    [No Abstract]   [Full Text] [Related]  

  • 12. Ribociclib (Kisqali) for advanced or metastatic breast cancer.
    Med Lett Drugs Ther; 2017 Oct; 59(1532):e178-e179. PubMed ID: 29039822
    [No Abstract]   [Full Text] [Related]  

  • 13. CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions.
    Spring LM; Wander SA; Zangardi M; Bardia A
    Curr Oncol Rep; 2019 Feb; 21(3):25. PubMed ID: 30806829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
    Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
    Hecht KA; Selby C
    Ann Pharmacother; 2019 Feb; 53(2):195-203. PubMed ID: 30079740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Kwapisz D
    Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
    Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
    PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
    Konecny GE
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.